Citation Impact
16 standout
Citing Papers
HER2-targeted therapies in cancer: a systematic review
2024 Standout
Tumor biomarkers for diagnosis, prognosis and targeted therapy
2024 Standout
Works of Gary Mo being referenced
Phase 1 trial of olaratumab monotherapy and in combination with chemotherapy in pediatric patients with relapsed/refractory solid and central nervous system tumors
2021
ANNOUNCE: A randomized, placebo (PBO)-controlled, double-blind, phase (Ph) III trial of doxorubicin (dox) + olaratumab versus dox + PBO in patients (pts) with advanced soft tissue sarcomas (STS).
2019
Author Peers
| Author | Oncology | PRM | Molecular Biology | Last Decade | Papers | Cites |
|---|---|---|---|---|---|---|
| Gary Mo | 67 | 67 | 27 | 20 | 143 | |
| Gina L. Barnes | 10 | 39 | 371 | |||
| S. S. Sidhu | 5 | 22 | 311 | |||
| Andréia de Fátima Nascimento | 8 | 16 | 1 | 14 | 406 | |
| Heinrich Trischmann | 33 | 92 | 648 | 41 | 1.7k |
All Works
Login with ORCID to disown or claim papers
Loading papers...